business / news / / NDTV Profit
Sun Pharmaceuticals Ltd. appears to be confident about its acquisition of Organon.
Sun Pharma projects $350 million in cost synergies from the Organon acquisition over 2–4 years.
KEY POINTS
- The Organon acquisition will be financed with $2–2.5 billion from Sun Pharma’s surplus and $9.25–9.75 billion in external borrowing.
- Combined entities are currently generating $2.5 billion in cash, expected to grow post-acquisition.
- The acquisition, valued at $11.75 billion, is expected to complete in early 2027 pending approvals.
COMPANIES
Summarized by Newsio from NDTV Profit. How we summarize →